Pneumococcal Infections
📧 Sign up to get email alerts when something new happens for Pneumococcal Infections.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2020-10-01Clinical Trial Update: Response of United Kingdom (UK) Infants to a Reduced Primary Schedule With Meningococcal C and Pneumococcal Conjugate Vaccines [Phase 4]
A Phase 4 trial evaluating the immune response of UK infants to a reduced primary vaccination schedule including meningococcal C and pneumoc…
-
CLINICAL_TRIALS trial_result · 2020-06-29Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When Administered Concomitantly With Influenza Vaccine in Healthy Adults 50 Years of Age or Older (V114-021/PNEU-FLU) [Phase 3]
Phase 3 study evaluating safety, tolerability, and immunogenicity of the pneumococcal conjugate vaccine V114 when administered with an influ…
-
CLINICAL_TRIALS trial_result · 2020-06-04Clinical Trial Update: A Trial To Evaluate A Multivalent Pneumococcal Conjugate Vaccine In Healthy Adults 50-85 Years Of Age [Phase 2]
Phase 2 trial update for a multivalent pneumococcal conjugate vaccine in healthy adults 50-85; results posted after completion.
-
CLINICAL_TRIALS trial_result · 2020-04-20Clinical Trial Update: Immunogenicity and Safety Study of NBP606 in Healthy Toddlers [Phase 3]
Phase 3 trial update reporting immunogenicity and safety of NBP606 in healthy toddlers for pneumococcal infections.
-
CLINICAL_TRIALS trial_result · 2020-04-20Clinical Trial Update: Immunogenicity and Safety Study of NBP606 in Healthy Infants [Phase 3]
Phase 3 immunogenicity and safety study of NBP606 in healthy infants completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2020-02-05Clinical Trial Update: Evaluation of the Safety and Immunogenicity of Sequential Administration of Prevnar 13™ and Pneumovax™ 23 in Healthy Participants 50 Years of Age and Older (V110-029) [Phase 3]
Phase 3 trial evaluating safety and immunogenicity of sequential administration of Prevnar 13 and Pneumovax 23 in adults 50+; study complete…
-
CLINICAL_TRIALS trial_result · 2020-01-02Clinical Trial Update: Assess the Immunogenicity of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine [Phase 3]
Phase 3 trial update assessing immunogenicity of GSK's 10-valent pneumococcal conjugate vaccine has completed.
-
CLINICAL_TRIALS trial_result · 2019-12-26Clinical Trial Update: Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age [Phase 2]
Phase 2 trial update evaluating safety and immunogenicity of a multivalent pneumococcal conjugate vaccine in adults aged 60-64; results post…
-
CLINICAL_TRIALS trial_result · 2019-12-10Clinical Trial Update: A Safety And Immunogenicity Study Of A 13-valent Pneumococcal Conjugate Vaccine In Japanese Subjects Aged 6 To 64 Years. [Phase 3]
A Phase 3 trial evaluated safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in Japanese adults and adolescents (6-64 y…
-
CLINICAL_TRIALS trial_result · 2019-10-23Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Lots of V114 in Healthy Infants (V114-008) [Phase 2]
Phase 2 trial evaluating two lots of V114 in healthy infants to assess safety, tolerability, and immunogenicity has completed with results p…
-
CLINICAL_TRIALS trial_result · 2019-08-20Clinical Trial Update: Enhancing a Sustainable Pharmacy-based Immunization Program in Two States [NA]
Completed clinical trial assessing a sustainable pharmacy-based immunization program in two states; results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2019-08-14Clinical Trial Update: Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in PPSV23-vaccinated Healthy Adults ≥65 Years of Age (V114-007) [Phase 2]
Phase 2 trial evaluating safety, tolerability, and immunogenicity of V114 compared with Prevnar 13 in adults ≥65 previously vaccinated with …
-
CLINICAL_TRIALS trial_result · 2019-04-30Clinical Trial Update: Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-004) [Phase 1, Phase 2]
A Phase 1/2 trial evaluating safety, tolerability, and immunogenicity of the V114 pneumococcal vaccine in healthy adults and infants complet…
-
CLINICAL_TRIALS trial_result · 2019-04-30Clinical Trial Update: A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003) [Phase 2]
Phase 2 trial comparing Pneumococcal Conjugate Vaccine V114 to a marketed vaccine (V114-003) for Pneumococcal Infections; completed with res…
-
CLINICAL_TRIALS trial_result · 2019-04-02Clinical Trial Update: Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006) [Phase 2]
Phase 2 trial evaluating safety, tolerability, and immunogenicity of two V114 formulations in adults 50+ with completed results.
-
CLINICAL_TRIALS trial_result · 2019-03-18Clinical Trial Update: Safety and Tolerability Study for the Pneumococcal Conjugate Vaccine V114 Versus Prevnar™ (V114-001) [Phase 1]
Phase 1 safety and tolerability trial comparing V114 to Prevnar for pneumococcal infection indications has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2018-12-13Clinical Trial Update: The Safety, Tolerability, and Immunogenicity Profiles of a Single Dose of V114, PNEUMOVAX® 23, or PREVNAR 13® in Adults 50 Years of Age or Older (V114-002) [Phase 2]
Phase 2 trial assessing safety, tolerability, and immunogenicity of a single dose of V114, PNEUMOVAX 23, or PREVNAR 13 in adults 50+; result…
-
CLINICAL_TRIALS trial_result · 2018-11-26Clinical Trial Update: Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine. [Phase 3]
Phase 3 safety and immunogenicity results for a booster dose of GSK's 10-valent pneumococcal conjugate vaccine have been completed with resu…
-
CLINICAL_TRIALS trial_result · 2018-04-17Clinical Trial Update: A Study to Evaluate the Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-005) [Phase 1, Phase 2]
Clinical trial evaluating safety, tolerability, and immunogenicity of V114 in healthy adults and infants (Phase 1/2) has completed with resu…
-
CLINICAL_TRIALS trial_result · 2018-04-06Clinical Trial Update: Safety, Tolerability, and Efficacy Study of Prophylactic S. Pneumoniae Vaccine Following Challenge With S. Pneumoniae [Phase 2]
Phase 2 clinical trial update evaluating the safety, tolerability, and efficacy of a prophylactic Streptococcus pneumoniae vaccine after del…
-
EMA withdrawal · 2017-11-24EMA Withdrawn: Prevenar (pneumococcal oligosaccharide serotype 18C;Pneumococcal polysaccharide serotype 19F;Pneumococcal polysaccharide serotype 23F;Pneumococcal polysaccharide serotype 4;Pneumococcal polysaccharide serotype 6B;Pneumococcal polysaccharide serotype 9V;Pneumococcal polysaccharide serotype 14) — Pfizer Limited
European Medicines Agency withdrew Prevenar from the market (pneumococcal serotypes) handled by Pfizer Limited.
-
CLINICAL_TRIALS research · 2017-09-05Clinical Trial Update: Humoral Determinants of Immunity to Pneumococcal Infection [Phase 4]
Phase 4 clinical trial update studying humoral determinants of immunity to pneumococcal infection, completed.
-
CLINICAL_TRIALS trial_result · 2017-06-26Clinical Trial Update: A Phase I Clinical Trial of a 13-valent Pneumococcal Conjugate Vaccine and 14-valent Pneumococcal Conjugate Vaccine in Adults [Phase 1]
Phase I clinical trial update on LG Life Sciences' 13-valent and 14-valent pneumococcal conjugate vaccines in adults has been completed.
-
CLINICAL_TRIALS trial_result · 2017-06-21Clinical Trial Update: The Effect of Milk Components on the Response to the Pneumonia Vaccine in Senior Citizens
A completed UC Davis clinical trial evaluated whether milk components influence the immune response to pneumococcal vaccines in elderly adul…
-
CLINICAL_TRIALS trial_result · 2017-05-10Clinical Trial Update: Evaluation of Pneumococcal Vaccine Formulations in Elderly [Phase 1]
GlaxoSmithKline conducted a Phase 1 evaluation of pneumococcal vaccine formulations in elderly adults; the study has completed.